Reducing Immunogenicity of a Clearing Agent for Antibody Therapy
Author Information
Author(s): D Marshall, RB Pedley, JA Boden, R Boden, RG Melton, RHJ Begent
Primary Institution: Cancer Research Campaign Laboratories, Department of Clinical Oncology, Royal Free Hospital School of Medicine, London
Hypothesis
Can polyethylene glycol (PEG) modification reduce the immunogenicity of a galactosylated streptavidin clearing agent without affecting its effectiveness?
Conclusion
PEG modification successfully reduced the immunogenicity of the galactosylated streptavidin clearing agent, but it also inhibited effective clearance of the antibody from circulation.
Supporting Evidence
- PEG modification reduced the immune response in mice after injection of gal-streptavidin.
- 2.5 PEG gal-streptavidin showed a lower anti-gal-streptavidin response compared to unmodified gal-streptavidin.
- 5 PEG gal-streptavidin resulted in very low levels of anti-gal-streptavidin antibodies in most mice.
Takeaway
Scientists wanted to make a medicine that helps clear cancer-fighting antibodies from the body without causing allergic reactions. They found that adding a special chemical made it less likely to cause allergies, but it also made the medicine work less well.
Methodology
Mice were injected with either gal-streptavidin or PEG-modified gal-streptavidin, and their immune responses were measured through antibody titres over time.
Limitations
The study was conducted in mice, and the effects in humans may differ; also, the degree of PEG modification may affect the results.
Participant Demographics
Immunocompetent mice were used in the study.
Want to read the original?
Access the complete publication on the publisher's website